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Background: Nanotechnology has received great attention since a decade for the treatment of different varieties
of cancer. However, there is a limited data available on the cytotoxic potential of Temozolomide (TMZ)
formulations. In the current research work, an attempt has been made to understand the anti-metastatic effect of
the drug after loading into PLGA nanoparticles against C6 glioma cells.
Nanoparticles were prepared using solvent diffusion method and were characterized for size and morphology.
Diffusion of the drug from the nanoparticles was studied by dialysis method. The designed nanoparticles were also
assessed for cellular uptake using confocal microscopy and flow cytometry.
Results: PLGA nanoparticles caused a sustained release of the drug and showed a higher cellular uptake. The drug
formulations also affected the cellular proliferation and motility.
Conclusion: PLGA coated nanoparticles prolong the activity of the loaded drug while retaining the anti-metastatic
activity.
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Glioblastoma multiforme is WHO classified grade IV type
of brain tumors depicting pleomorphism and atypical nu-
clei [1]. The current therapeutic modality for the treat-
ment includes surgery followed by chemotherapy and
radiation. Despite the progress in understanding of mo-
lecular basis in the gliomas, the prognosis of tumors re-
mains dismal [2]. The main reason for the poor prognosis
is the complexity of the brain and presence of Blood Brain
Barrier (BBB). This comprises of endothelial cells that
does not allow entry of exogenous material, bacteria,
viruses and chemotherapeutic agents. Further, the expres-
sion of the efflux transporters adds to its complexity [3].
However, BBB allows the passage of small sized parti-
cles that are hydrophobic in nature [4]. Nanoparticles viz.
solid lipid nanoparticles, polymeric nanoparticles, nano
emulsions have been fabricated and used against gliomas* Correspondence: rajani.athawale@gmail.com; rgude@actrec.gov.in
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reproduction in any medium, provided the or[5-7]. Small sized particles are better permeated though
the barrier with the target ability to the cancerous cells.
TMZ has been a drug of choice and is used as a first line
agent for the treatment of gliomas after its surgical resec-
tion. However, due to a very short half life of 1.8 h and
protein binding of 15% [8,9] repeated administration of
the drug is required. In addition, less site specificity
is demonstrated by the drug and thus the amount of
the drug reaching the tumor site becomes limited. The
probability of aiming the cancerous cells with sustained
release of the loaded drugs/agents by nanoparticles
prompted us to undertake the present work. Nanoparticles
loaded with doxorubicin, daunorubicin, epirubicin, temo-
zolomide, methotrexate and many other such chemothera-
peutic agents have been prepared and characterized for
various physico-chemical properties [10-14].
Polymeric nanoparticles are amongst the most pre-
ferred delivery system for treatment of cancers due to
higher penetrability, sustainability, degradability and bet-
ter payload. The reason for selecting PLGA is based on
its tunable properties and biodegradability. Biodegrad-
ability leads to formation of lactic acid and glycolic acid
that are readily cleared form the body as by products. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of TMZ encapsulated in nanoparticulate formulations
till date.
In this purview, we had decided to fabricate PLGA
nanoparticles loaded with anti cancer agent TMZ for
targeting glial cells. The prepared nanoparticles could
thus reach the target cells by passage though the BBB
and demonstrate better penetrability though the cancer-
ous cells. Further, we have evaluated the performance
index of both the free and encapsulated drug. The re-
sults clearly suggest the applicability of PLGA coated
nanoparticles for the management of gliomas.
Methods
Cell lines
The C6 glioma cell line was procured from NCCS,
Pune, India. It was maintained in HAM’s 12 medium
(GIBCO) supplemented with 10% heat inactivated fetal
bovine serum, FBS (GIBCO) and primocin (100 μg/mL).
Cultures were maintained at 37°C in 5% CO2 humidified
atmosphere.
Materials
Temozolomide was a generous gift sample from Cipla
Pvt. Ltd. Vikhroli, Mumbai. PLGA was obtained as a gift
sample from PURAC (PDLG 50:50 grade). Poloxamer
188 (Lutrol F 68) was obtained as a gift sample from
BASF Ltd. Mumbai. All the other chemicals/reagents used
were either of analytical grade or the highest purity com-
mercially available.
Preparation of nanoparticles
PLGA nanoparticles were prepared by a method princi-
pally involving solvent diffusion technique [15]. Briefly,
50 mg of PLGA was solubilised in 4 mL of acetonitrile.
To the same solution 30 mg of the drug was added and
solubilised. The above solution was emulsified with an
aqueous solution (4 mL) comprising of 0.5% poloxamer
188 using IKA -18 Ultraturrax. Emulsified organic solv-
ent was carefully poured into 8 mL of prechilled 0.5%
poloxamer 188 solution kept stirring over a magnetic
stirrer. Solvent was allowed to slowly diffuse leaving be-
hind homogenous nanoparticles. Particle size and zeta
potential for the developed particles were noted using
Malvern Zetasizer 90S.
Particle size analysis and polydispersity index
measurements
Particle size and polydispersity index for the developed
nanoparticles were noted using Malveren Zetasizer in-
strument 90S (Ver 6.12.). Particle size indicates the aver-
age size acquired by the nanoparticles when dispersed in
water whereas the polydispersity index depicted the
homogeneity in distribution of these particles. In ourstudy, 20 μL of the nanoparticulate suspension was suit-
ably diluted with HPLC grade water in the polystyrene
cuvette. The cuvette was then placed in the pathway of
scattered light to record the fluctuations in the intensity
of the light due to the presence of the particles. The in-
tensity of the scattered light was measured at 90° using
Malvern software to give the hydrodynamic diameter
and the polydispersity index [16].
Zeta potential and diffusion coefficient measurements
Zeta potential measurements enable to determine surface
charge acquired by the particles in solution. Samples were
diluted using the procedure discussed for particle size
measurement. A dip cell with electrode was inserted into
the cuvette and then placed in Malvern Zetasizer 90 S.
Diffusion coefficients and the particle mobility was noted
for each sample. An average of approximately 15 runs was
measured at 90° at the stationery level in the cylindrical
cell. Auto correlated software depicted the zeta potential
values for each sample depending upon the mobility of the
particles towards the electrode.
In- vitro dissolution study
Diffusion though dialysis membrane was assessed to de-
termine the diffusion and further dissolution of the drug
in the dissolution medium. Quantification of the drug
from the withdrawn aliquots during in-vitro dissolution
was performed using developed and prevalidated UV
method (JASCO). Pure Drug and nanoparticle batches
equivalent to 20 mg of drug were weighed and trans-
ferred to dialysis membrane {cut off 6-8 KDa and diam-
eter of 21.5 mm (Hi media dialysis membrane no. 50)
sealed at one end by thread. Approximately, 1 mL of dis-
solution medium (sodium acetate buffer pH 5) was
added in these bags, and another end was sealed. Prepared
dialysis bags were dialyzed by suspending in 500 mL of
pH 5 sodium acetate buffer placed in dissolution flask
(Apparatus: Dissolution tester: Electrolab 6 T). Dissolution
was performed in pH 5 sodium acetate buffer dissolution
medium at rotation speed of 100 rpm. Intermittently ali-
quots were withdrawn at prefixed time intervals. Each
time 1 mL was withdrawn and replenished with the same
amount of dissolution medium during the study. Volume
of the aliquots was made to 10 mL with dissolution
medium and absorbance was measured at λmax of
255 nm on a UV spectrophotometer. Calculation for %
drug release was performed at each time point and graphs
indicating % drug released vs. time were plotted and are
represented in Figure 1.
Cellular proliferation using MTT cytotoxicity assay
Cytotoxicity was determined using MTT assay as previ-
ously reported [17,18]. Briefly, 2500 and 1500 cells/well
were seeded in a 96-well plate respectively. After 24 h
Figure 1 In vitro Dissolution profile of pure drug and TMZ- PLGA nanoparticles. An immediate release of 30% fraction of drug
(unentrapped drug) in initial 2 h is seen, followed by sustained release of drug up to 120 h indicating the biphasic release pattern for the drug
which is typical of PLGA nanoparticles.
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nanoparticles and PLGA nanoparticles loaded with TMZ
at varying doses of (1,500-0.01 μg/mL). Plates were then
incubated at 37°C for 72 h and 96 h in CO2 incubator.
The drug was discarded and the wells were washed twice
with PBS at respective time points. MTT (1 mg/mL) was
added to all the wells and incubated overnight. The
plates were later centrifuged and the supernatant was fi-
nally discarded. The formazon crystals formed were dis-
solved in DMSO and the readings were taken using
ELISA plate reader at dual wavelengths of 540/690 nm
respectively. IC50, the concentration required to kill 50%
of the cells by TMZ was calculated. The graph was plot-
ted on a logarithmic scale as percentage viability versus
drug concentration and is represented in Figure 2.
Colony formation assay
Clonogenic assay was done to assess the long term cyto-
toxicity of different formulations. 600 cells were seeded
in a 35 mm plate and after stabilization [19] treated with
developed formulations: PLGA formulations (Drug loaded
and blank) and pure drug. These were removed after an
incubation period of 24 h, and the plates were washed
with PBS to remove traces of the drug. Cells were later in-
cubated in the presence of complete media for a period of
8–10 days. Fixation was done using 70% chilled methanol
followed by staining using 1% crystal violet. Colonies con-
taining 50 or more cells were counted and the results were
plotted as number of colonies versus drug/formulation
(Figure 3).
Wound scratch assay
Wound scratch assay was performed as per the earlier
reports [18,20,21]. Approximately, 0.6 million cells wereseeded into 35 mm plates. On the following day, cells
were treated with 2 μg/mL mitomycin C for 1 h. The
cells in the centre of the plates were later scraped using
a sterile tip so as to form a wound. Sub-toxic doses of
TMZ (75 μg/mL and 150 μg/mL), TMZ loaded formu-
lations and PLGA formulations (equivalent to pure
drug) were then added and incubated for 24 h. Drug
formulations were removed and the plates were fixed
using 70% methanol. The wound width was measured
using the AxioVision Rel 4.8 imaging software, and the re-
sults were plotted as percent wound closure with respect
to control. The controls were considered to be covered
100%. Results are represented in Figure 4.
Cellular morphology in presence of TMZ loaded in
nanoparticulate formulation
Haematoxylin-Eosin (HE) staining was performed to
observe the morphological changes upon drug treat-
ment as described previously [17,18]. Sub-confluent
cells were allowed to be grown on coverslips. Cells
were then treated with TMZ, PLGA blank formulations
and TMZ loaded into nanoparticulate formulations
(concentration equivalent to 75 μg/mL) as done earl-
ier and fixed using 70% chilled methanol. The cover
slips were then stained using haematoxylin and eosin
subsequently. Mounting was done on the glass slides
using DPX mountant. Cells were later observed under
Zeiss upright microscope. The results are shown in
Figure 5.
Cellular uptake using confocal microscopy
The uptake of nanoparticles was performed using parti-
cles loaded with FITC, a hydrophilic dye. Sub-confluent
cultures of C6 glioma were treated with only FITC and
Figure 3 Clonogenic assay for pure drug, TMZ loaded PLGA nanoparticle formulations and placebo PLGA nanoparticles. The numbers
of colonies for untreated and pure drug treated cells were found to be 221.00 ± 15.56 and 67.00 ± 10.26 respectively. However, in case of drug
loaded nanoparticles the number of colonies were 75.00 ± 8.00, 70.66 ± 4.00 at concentrations of 75 μg/mL and 150 μg/mL respectively. (*P< 0.05).
Figure 2 MTT assay performed for the pure drug and drug loaded PLGA nanoparticles. The observed IC50 was 150 μg/mL TMZ in pure
form on C6 glioma irrespective of the time. However, the same drug when loaded into nanoparticles demonstrated an IC50 of 200 μg/mL and
150 μg/mL after 72 h and 96 h, respectively.
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Figure 4 Wound Scratch assay to assess the role of developed nanoformulations on cellular motility. The wound coverage was found to
be 66.84 ± 5.81, 67.59 ± 3.39 for TMZ and loaded nanoparticles at 75 μg/mL dose compared to the control (100%). A significant decrease in
wound coverage at 150 μg/mL of nanoparticles concentration i.e 53.00 ± 5.82 is observed. However, no significant difference between placebo
and control groups was observed (*P < 0.05).
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were later washed with PBS and fixed using 1% parafor-
maldehyde (PFA). The cells were then treated with DAPI
and then washing was done thrice with PBS. Mounting
of coverslips was done using 2.5% DABCO on glass
slides and then sealed with nail paint. Acquisition was
done on LSM 510 confocal microscope from Zeiss at
63X. LSM image browser software was used for data ana-
lysis (Figure 6).
Cellular uptake using flow cytometry
Flow cytometric analysis was done to confirm our previ-
ous findings. Sub-confluent cultures of C6 glioma weretreated with FITC and its loaded nanoparticles as done
earlier [22]. Cells were thereafter harvested and fixed
using 1% PFA. Cells were then washed using PBS and later
suspended in the same. Acquisition was done using FACS
Calibur and the results were analysed by CellQuest soft-
ware (Figure 7).
Statistical analysis
All the experiments had been performed at least thrice.
The results are indicated as Mean ± SD. One way ANOVA
was used for the purpose of statistical significance. The re-
sults were considered to be statistically significant where
*P < 0.05.
Figure 5 Changes in cellular morphology using HE staining. The spindle shape cells of C6 glioma is distorted after treatment with free TMZ
and TMZ loaded formulations. Further, stress on the spindle fibres with further rounding up of the cells is being observed.
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Fabrication of nanoparticles
Solvent diffusion method was used for the fabrication of
nanoparticles. Developed nanoparticles were subjected to
particle size and zeta potential assessment. The particle
size for the pure drug was found to be 1256 ± 82 nm
(Approximately 1.3 μm crystalline structure particles).
A size range of 150-160 nm was found for the developed
nanoparticles with poly dispersity index values suggestingFigure 6 Immunofluorescence studies for cellular uptake of develope
fluorescence indicating absence of its uptake. However, cells treated with F
is stained with DAPI represented in dark blue colour.that the developed nanoparticles were monodisperse. The
developed nanoparticles were then lyophilized and the as-
sessment of the size was performed post lyophilisation.
The developed lyophilized nanoparticulate formulation
maintained the particle size even after reconstitution indi-
cating stability and robustness of the developed nanoparti-
cles. Zeta potential for the pure drug was found to be
17.40 ± 0.256 mV and for the developed nanoparticles was
found to be − 20.50 ± 0.069 mV.d nanoparticles. Cells treated with FITC showed almost negligible
ITC loaded nanoparticles exhibited strong green fluorescence. Nucleus
Figure 7 Cellular uptake using flow cytometry. Uptake of
PLGA-poloxamer coated nanoparticles is higher (pink color) than the
uncoated nanoparticles (green color) and cell treated with only FITC
(red color). Black colour indicates background fluorescence because
of only cells. Both 2D and 3D representations are shown.
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particles viz. solvent evaporation, microfluidisation, solv-
ent diffusion, nanoprecipitation and salting out. The
designed nanoparticles were developed successfully with
solvent diffusion technique with acetonitrile as organic
solvent. As the particles were designed for treatment of
glioblastoma multiforme, the major obstacle to the deliv-
ery of particles would be passage though the BBB. How-
ever, BBB permit passage of small size entities (below
200 nm) which are hydrophobic in nature and hence
particle size is an important parameter for entities aim-
ing to pass the blood brain barrier. As the particle size
range of our designed nanoparticles was below 200 nm
better permeation can be expected though the barrier.
The surface charge on the particle could be determined
by the zeta potential. Negative values for the pure drug
indicate that the charge on the surface is negative. The
negatively charged drug particles are taken up the liver
and further phagocytosized, thus only a small fraction of
the drug remains in the circulation [23,24]. With the de-
signed nanoparticles negative charge of the particles was
maintained with the readings at the higher end of the
negative charge. Higher values of the zeta potential de-
termine the stability of the particle. Further, transmission
electron microscopy images depicted formation of
roughly round PLGA drug loaded nanoparticles. Poloxa-
mer 188 layer with the thickness of around 6-10 nm was
found using transmission electron microscopy [15].
In vitro dissolution profile
Dissolution was performed in sodium acetate buffer pH 5,
considering the stability of the drug. TMZ is unstable at
physiological pH and rapidly undergoes hydrolysis to form
MTIC and AIC as metabolites. Pure drug diffuses out of
the dialysis bag within 2 h as indicated in the graph plottedfor TMZ. This reading can be correlated with the half life
of the drug being 1.8 h that means the drug is readily avail-
able for its action in vivo. However, the developed nanopar-
ticles demonstrated a slow release pattern of the drug
when loaded into PLGA nanoparticles. The half life of the
drug is extended as indicated from dissolution profile. An
immediate release of 30% fraction of drug (unentrapped
drug) in initial 2 h is seen, followed by sustained release of
drug up to 120 h indicating the biphasic release pattern for
the drug which is typical of PLGA nanoparticles. The de-
veloped nanoparticles could sustain the drug release and
extend the half life of drug. The data warrants the avoid-
ance of repeated administration of TMZ and this would be
of clinical significance because the developed formulation
avoids repeated administration of the active component
in vivo. This action was further confirmed and correlated
with performed in vitro cell line study.Nanoparticles exert anti-proliferative effects in a dose
and time dependent manner
Time and dose-dependent based MTT studies were per-
formed to determine the IC50 of TMZ (72 h and 96 h).
The observed IC50 for pure TMZ was found out to be
150 μg/mL against C6 glioma irrespective of the time.
However, the same drug when loaded into nanoparticles
demonstrated an IC50 of 200 μg/mL and 150 μg/mL
after 72 h and 96 h, respectively. As the time of exposure
of formulations to the cells was increased, IC50 showed
a significant decrease. This further correlated with the
dose. As the dose of the pure drug and drug loaded
formulation was increased IC50 of the compound de-
creased. However, for pure drug IC50 was concentration
but not time dependent. The developed formulations
released the drug at a very slow rate and hence a small
proportion of drug is available to exhibit action each
time (drug release profile in Figure 2). The obtained re-
sults can be correlated with the dissolution profile of
the drug. The diffusion of the drug from the formula-
tion continued for more than 120 h. Hence, even after
96 h IC50 for pure drug and drug loaded nanoparticles
did not match, confirming slow release of the drug
from the developed formulation, as well as time and
concentration dependent cytotoxicity of developed for-
mulations. Further, to confirm the absence of cytotoxic
action of the excipients used in the developed formula-
tion, MTT assay was also performed for the blank formu-
lation. High IC50 (> 1000 μg/mL after 96 h exposure)
value of the blank formulation depicts the safety of the
polymer and other excipients used for fabricating the
nanoparticles. Based on these observations, 75 μg/mL
and 150 μg/mL of TMZ in free and loaded form were se-
lected for performing the subsequent experiments with
24 h exposure.
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Anti-proliferative activity of the cells was performed
using clonogenic assay. The numbers of colonies for un-
treated and pure drug treated cells were found to be
221.00 ± 15.56 and 67.00 ± 10.26. The number of col-
onies for drug loaded nanoparticles was found to be
75.00 ± 80, 70.66 ± 40 at concentrations of 75 μg/mL and
150 μg/mL respectively (P < 0.05). Cancer cells show a
self sufficiency towards growth signals [25]. These re-
sults indicate that the cells lose the ability to replicate in
the presence of drug and its formulations. The possible
mechanism might be due to inhibition of EGFR and
MAPK pathways by TMZ as reported earlier, that play
key roles in the process of proliferation [26,27].
Nanoparticles affect motility of C6 glioma cells
Both pure TMZ and its nanoparticles formulations at
dosage of 75 μg/mL showed a similar reduction in motility.
The wound coverage was found out to be 66.84 ± 5.81,
67.59 ± 3.39 for pure and nanoparticles at 75 μg/mL dose
compared to the control (100%). However, there was a sig-
nificant decrease in wound coverage at 150 μg/mL of
nanoparticles concentration i.e 53.00 ± 5.82 (P < 0.05).
There was no significant difference between placebo and
control groups respectively. The differences in migration
between pure drug and drug loaded nanoparticles formu-
lation (150 μg/mL) can be attributed to the slower diffu-
sion of the drug from the nanoparticles. The effect of
TMZ on Rho GTPase signaling might be the possible
reason for hindering migration as earlier reported [27].
Changes in cellular morphology upon TMZ and PLGA
nanoparticles treatment
C6 glioma cells exhibits atypical nuclei with pleomorph-
ism characteristic of human glioma cancer. The spindle
shape cells of C6 glioma is distorted after treatment with
free TMZ and TMZ loaded formulation. Stress on the
spindle fibres with further rounding up of the cells is being
observed. Further, there is a decrease in cell volume and
number with both the regimens, demonstrating equal effi-
cacy of the developed drug loaded nanoparticles.
Immuno fluorescence showed a higher uptake of
developed nanoparticles
C6 glioma cells were treated with FITC loaded into
PLGA nanoparticles. Images for the uptake are depicted
in Figure 6. Cells treated with pure dye showed almost
negligible or background fluorescence indicating no up-
take of the dye by the cells. However, cells treated with
FITC loaded nanoparticles exhibited strong green fluor-
escence. The nucleus of the cells is stained with DAPI
represented in blue colour. These results indicated that
the developed nanoparticles are able to modulate the
uptake of hydrophilic dye after its encapsulation inthe particle. PLGA being a hydrophobic polymer with
tunable properties masks the entity of FITC, a hydro-
philic agent not readily permeating into the cells. Thus,
it can be concluded that the uptake of hydrophilic/
amphipathic agent will be enhanced by using PLGA de-
signed nanoparticles.Flow cytometric analysis showed an increase in uptake
of developed nanoparticles
To further corroborate our earlier findings using confocal
microscopy, we had performed the cellular uptake of the
developed nano formulations in C6 glioma cells by flow
cytometry. As can be seen in Figure 7, uptake of PLGA-
poloxomer is high (pink color) than the uncoated (green
color) and cell treated with only FITC (red color). These
observations further substantiate our earlier findings.Conclusions
The present study was performed to develop effective
formulations targeting across the BBB. TMZ loaded
nanoparticles were successfully prepared using solvent
evaporation method. The developed nanoparticles exhib-
ited slow release of the drug with prolongation of its half
life. Further, cellular uptake of the nanoparticles was en-
hanced as confirmed using confocal and flow cytometry.
These properties certainly enhance the safety profile of
the drug with reducing its toxicity. Hence, it may be con-
cluded Poly Lactic glycolic acid (PLGA) nanoparticles
sustain the cytotoxic action of TMZ in C6 Glioma cells.
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